ALK gene fusion occurs in approximately 3%-5% of NSCLC patients. Currently, there are 5 FDA approved tyrosine kinase inhibitors (TKI): crizotinib (first generation), ceritinib, alectinib, brigatinib (second generation), lorlatinib (third generation).